Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jacobio Pharmaceuticals has announced that China’s CDE has approved their Investigational New Drug application for JAB-23E73, a Pan-KRAS inhibitor aimed at treating various tumor mutations. The drug, which has already had its IND application approved by the U.S. FDA, is poised to enter phase I/IIa clinical trials for advanced solid tumor patients in China and the U.S. This development could potentially benefit the yearly 2.7 million new patients with KRAS-related mutations.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.